Integrative Strategy for Investigating the Interactions between STING and Small-Molecule Ligands

Area of Science:

• Immunology
• Biochemistry
• Structural Biology

Background:

• Stimulator of interferon genes (STING) is crucial for innate immune activation.
• The precise mechanism of how small-molecule agonists like DMXAA activate STING remains incompletely understood.
• Understanding STING activation is vital for developing immunotherapies.

Purpose of the Study:

• To elucidate the molecular interaction mechanism between STING and its agonist DMXAA.
• To identify key structural features of DMXAA responsible for STING activation.
• To explore the therapeutic potential of STING-DMXAA interaction modulators.

Main Methods:

• Biochemical assays and computer simulations were integrated to study STING-DMXAA interactions.
• Design and synthesis of DMXAA derivatives based on crystal structure analysis.
• In vitro and in vivo experiments to assess the biological activity of DMXAA derivatives.

Main Results:

• The carboxyl moiety of DMXAA was identified as a critical pharmacophore for STING activation.
• Disruption of the hydrogen bond between DMXAA's carboxyl group and STING's Thr262 residue inhibits STING.
• A novel DMXAA derivative (DNHM) demonstrated potent STING inhibition, reducing interferon production and STING-associated inflammation in vitro and in vivo.

Conclusions:

• This study provides novel insights into the STING-ligand binding mechanism.
• The carboxyl group's interaction with Thr262 is essential for STING activation by DMXAA.
• Targeting STING-ligand interactions offers a promising strategy for managing inflammatory diseases.